Human cytomegalovirus and risk of incident cardiovascular disease in UK Biobank
View/ Open
File version
Version of Record (VoR)
Author(s)
Hamilton, Elizabeth M
Allen, Naomi E
Mentzer, Alexander J
Littlejohns, Thomas J
Griffith University Author(s)
Year published
2021
Metadata
Show full item recordAbstract
BACKGROUND: Previous studies have yielded conflicting results on the association between human cytomegalovirus (HCMV) and cardiovascular disease (CVD). This study aimed to examine associations between HCMV and incident CVD, ischaemic heart disease (IHD) and stroke. METHODS: This study included 8,531 women and men of predominantly white ethnic background, aged 40-69 without prevalent CVD from the population-based UK Biobank study recruited between 2006-2010 with HCMV antibody levels measured. CVD was ascertained via linkage to health administrative records collected up to 2020. Multivariate Cox proportional-hazards models ...
View more >BACKGROUND: Previous studies have yielded conflicting results on the association between human cytomegalovirus (HCMV) and cardiovascular disease (CVD). This study aimed to examine associations between HCMV and incident CVD, ischaemic heart disease (IHD) and stroke. METHODS: This study included 8,531 women and men of predominantly white ethnic background, aged 40-69 without prevalent CVD from the population-based UK Biobank study recruited between 2006-2010 with HCMV antibody levels measured. CVD was ascertained via linkage to health administrative records collected up to 2020. Multivariate Cox proportional-hazards models were used to determine the association between HCMV seropositivity and incident CVD, IHD and stroke. HCMV seropositive antibody levels were split into tertiles to assess dose-response associations. RESULTS: Over a mean follow-up period of 10.2 years, HCMV seropositivity was not significantly associated with CVD (Cases = 626, Hazard Ratio (HR) =1.01, 95% Confidence Interval (CI) 0.86-1.20), IHD (Cases = 539, HR=1.03, 95% CI 0.87-1.24) or stroke (Cases = 144, HR=0.96, 95% CI 0.68-1.36). There was no evidence of dose-response associations with any outcome. CONCLUSION: We found no significant association between HCMV seropositivity and risk of CVD, IHD or stroke. Further research within understudied populations, such as those of non-white ethnicity, and other CVD subtypes is warranted.
View less >
View more >BACKGROUND: Previous studies have yielded conflicting results on the association between human cytomegalovirus (HCMV) and cardiovascular disease (CVD). This study aimed to examine associations between HCMV and incident CVD, ischaemic heart disease (IHD) and stroke. METHODS: This study included 8,531 women and men of predominantly white ethnic background, aged 40-69 without prevalent CVD from the population-based UK Biobank study recruited between 2006-2010 with HCMV antibody levels measured. CVD was ascertained via linkage to health administrative records collected up to 2020. Multivariate Cox proportional-hazards models were used to determine the association between HCMV seropositivity and incident CVD, IHD and stroke. HCMV seropositive antibody levels were split into tertiles to assess dose-response associations. RESULTS: Over a mean follow-up period of 10.2 years, HCMV seropositivity was not significantly associated with CVD (Cases = 626, Hazard Ratio (HR) =1.01, 95% Confidence Interval (CI) 0.86-1.20), IHD (Cases = 539, HR=1.03, 95% CI 0.87-1.24) or stroke (Cases = 144, HR=0.96, 95% CI 0.68-1.36). There was no evidence of dose-response associations with any outcome. CONCLUSION: We found no significant association between HCMV seropositivity and risk of CVD, IHD or stroke. Further research within understudied populations, such as those of non-white ethnicity, and other CVD subtypes is warranted.
View less >
Journal Title
The Journal of Infectious Diseases
Copyright Statement
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Note
This publication has been entered as an advanced online version in Griffith Research Online.
Subject
Biological sciences
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Clinical sciences
Human cytomegalovirus
UK Biobank
cardiovascular disease
ischaemic heart disease
longitudinal